Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• liraglutide (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Novo Nordisk Investigational Site
  Annaka-shi, Gunma, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Chitose, Hokkaido, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Chuo-ku Tokyo, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Chuo-ku, Tokyo, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Chuo-ku, Tokyo, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Chūōku, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Fukuoka-shi, Fukuoka, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Higashiosaka-shi, Osaka, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Hokkaido, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Ichikawa-shi, Chiba, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Iruma-shi, Saitama, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Izumisano, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Kashiwara-shi, Osaka, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Kawagoe-shi, Saitama, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Kobe-shi, Hyogo, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Kumamoto-shi,Kumamoto, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Mito-shi, Ibaraki, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Mito-shi, Ibaraki, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Miyazaki, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Naka-shi, Ibaraki, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Neyagawa-shi, Osaka, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Nishinomiya-shi, Hygo, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Nishinomiya-shi, Hyogo, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Okawa-shi, Fukuoka, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Osaka-shi, Osaka, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Osaka-shi, Osaka, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Oyama-shi, Tochigi, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Ōita, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Saga-shi,Saga, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Sapporo-shi, Hokkaido, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Sapporo-shi, Hokkaido, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Sapporo-shi, Hokkaido, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Sappro-shi, Hokkaido, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Shimotsuke-shi, Tochigi, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Shinjuku-ku, Tokyo, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Shizuoka, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Suita-shi, Osaka, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Takatsuki-shi, Osaka, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Tokyo, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Tokyo, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Tokyo, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Tokyo, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Tokyo, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Tokyo, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Yokohama, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Yokohama, Kanagawa, Japan
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Yokohama-shi Kanagawa, Japan
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• NNC9204-0530 (drug)
• liraglutide (drug)
• placebo (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Novo Nordisk Investigational Site
  Tempe, Arizona, United States
  Site recruitment: Not reported
• Novo Nordisk Investigational Site
  Lincoln, Nebraska, United States
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• NNC9204-1513 (drug)
• Glucagon (drug) — also listed as: GlucaGen®
• Placebo (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Novo Nordisk Investigational Site
  Berlin, Germany
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Glucagon (drug)
• Placebo (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Toronto General Hospital
  Toronto, Ontario, Canada
  Site recruitment: Recruiting

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Nasal Glucagon (drug) — also listed as: AMG504-1, LY900018
• Intramuscular Glucagon (drug) — also listed as: GlucaGen HypoKit

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Barbara Davis Center for Diabetes
  Aurora, Colorado, United States
  Site recruitment: Not reported
• Yale University
  New Haven, Connecticut, United States
  Site recruitment: Not reported
• University of Florida
  Gainesville, Florida, United States
  Site recruitment: Not reported
• Nemours Children's Clinic
  Jacksonville, Florida, United States
  Site recruitment: Not reported
• Riley Hospital for Children Indiana University Health
  Indianapolis, Indiana, United States
  Site recruitment: Not reported
• University of Minnesota
  Minneapolis, Minnesota, United States
  Site recruitment: Not reported
• UPA Buffalo
  Buffalo, New York, United States
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• LY3325656 (drug)
• Placebo (drug)
• Liraglutide (drug)
• Sitagliptin (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
  Singapore, Singapore
  Site recruitment: Not reported
• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
  Singapore, Singapore
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Closed loop with sensor and Insulin (drug) — also listed as: Novolog
• Closed loop with sensor, Insulin and Liraglutide (drug) — also listed as: Victoza

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Albert Einstein College of Medicine West Campus CRC
  The Bronx, New York, United States
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• GLP-1 (biological) — also listed as: Glucagon-like peptide-1
• Intravenous saline (biological)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Uppsala University
  Uppsala, Uppsala County, Sweden
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• liraglutide (drug) — also listed as: Victoza 6 mg/ml solution for injection in pre-filled pen
• Testosterone (drug) — also listed as: Androtop gel

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• University Medical Center Ljubljana
  Ljubljana, Slovenia
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Bihormonal Bionic Pancreas (device)
• Insulin Only Bionic Pancreas (device)
• Monitored for Hypoglycemia (other)
• Not Monitored for Hypoglycemia (other)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• MGH Diabetes Research Center
  Boston, Massachusetts, United States
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• RYGB (procedure)
• GLP-1 (drug) — also listed as: gut hormone

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Dept.Clinical and Experimental Medicine.Section of Diabetes.
  Pisa, Italy
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Liraglutide (drug) — also listed as: Victoza

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Bispebjerg University Hospital
  Copenhagen, Copenhagen Northwest, Denmark
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Placebo Oral Tablet (drug)
• Metformin (drug)
• Saline (drug)
• Exendin (9-39) (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Center for Diabetes Research
  Gentofte Municipality, Copenhagen, Denmark
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• liraglutide (drug)
• placebo (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Novo Nordisk Investigational Site
  Hellerup, Denmark
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• GLP-1 (drug) — also listed as: GLP-1 (7-36) amide
• placebo (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Papworth Hospital
  Cambridge, Cambridgeshire, United Kingdom
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Oral glucose tolerance test (other)
• Liquid mixed meal test (other)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Department of Gastrointestinal Surgery, Righospitalet
  Copenhagen, Capital, Denmark
  Site recruitment: Recruiting

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Control (drug) — also listed as: No Peptide or Atropine
• Xenin-25 without atropine (drug) — also listed as: xenin without atropine
• GIP without atropine (drug)
• Placebo with atropine (drug) — also listed as: Albumin (no peptide) with atropine
• Xenin-25 with atropine (drug) — also listed as: xenin and atropine
• GIP with atropine (drug) — also listed as: GIP and atropine
• GIP plus Xenin-25 without atropine (drug) — also listed as: GIP plus xenin without atropine
• GIP plus Xenin-25 with atropine (drug) — also listed as: GIP plus xenin with atropine

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Washington University School of Medicine
  St Louis, Missouri, United States
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML) (drug)
• lifestyle modification (other)
• sleeve gastrectomy (other)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Catholic University School of Medicine
  Rome, Italy
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Tablet Sitagliptin 100mg (evening before and morning of experiments) (drug)
• Intestinal Fructose administration (other)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Department of Surgery C, Rigshospitalet
  Copenhagen, Denmark
  Site recruitment: Recruiting

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Liraglutide combined with metformin (drug) — also listed as: Victoza®, Novo Nordisk
• Insulin glargine combined with metformin (drug) — also listed as: Lantus®, Sanofi
• Sitagliptin combined with metformin (drug) — also listed as: Januvia®, Merck & Co. Inc.

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• The Third Affiliated Hospital of Sun Yat-sen University
  Guangzhou, Guangdong, China
  Site recruitment: Not reported